Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
113 hedge funds and large institutions have $795M invested in Avadel Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 8 closing their positions.
214% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $4.96M
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
42% more capital invested
Capital invested by funds: $559M → $795M (+$236M)
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
14% more funds holding
Funds holding: 99 → 113 (+14)
1.87% more ownership
Funds ownership: 60.85% → 62.71% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$26.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.18M |
| 3 |
Morgan Stanley
New York
|
+$6.52M |
| 4 |
Janus Henderson Group
London,
|
+$5.72M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.6M |
| 2 |
CAC
Cowen and Company
New York
|
-$8.18M |
| 3 |
JP Morgan Chase
New York
|
-$4.75M |
| 4 |
D.E. Shaw & Co
New York
|
-$4.14M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.6M |
AVDL Hedge Fund Activity: Q4 2023 in Review
113 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2023, worth a combined $795M — up 42% from $559M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AVDL positions and 8 closed out — a net gain of 14 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $26.3M. The largest seller was Adage Capital Partners, cutting an estimated $17.6M.
- 113 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2023, up from 99 in Q3 2023.
- Funds reported $795M of Avadel Pharmaceuticals stock for Q4 2023, up 42% quarter-over-quarter.
- 22 funds opened new Avadel Pharmaceuticals positions in Q4 2023 and 8 closed out, a net change of +14 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2023 was Polar Capital Holdings, an estimated $26.3M added.
- The largest Avadel Pharmaceuticals seller in Q4 2023 was Adage Capital Partners, an estimated $17.6M sold.
Based on aggregated 13F filings for Q4 2023.